Fibrinolytic status in acute coronary syndromes: Evidence of differences in relation to clinical features and pathophysiological pathways

Thrombosis and Haemostasis

Volumn 108, Issue 1, 2012, Pages 32-40

  Shantsila, Eduard ^a   Montoro Garcia, Silvia ^a   Tapp, Luke D ^a   Apostolakis, Stavros ^a   Wrigley, Benjamin J ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Acute coronary syndromes; Fibrinolysis; Monocyte subsets; Monocyte platelet aggregates; Non ST elevation myocardial infarction; ST elevation myocardial infarction

Indexed keywords

ALPHA4 INTEGRIN; BETA2 INTEGRIN; CD14 ANTIGEN; CD16 ANTIGEN; CD163 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; GLYCOPROTEIN; I KAPPA B KINASE BETA; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TOLL LIKE RECEPTOR 4; UROKINASE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION;

ACUTE CORONARY SYNDROME; AGED; ANTIGENS, CD14; BIOLOGICAL MARKERS; BLOOD PLATELETS; CARBOXYPEPTIDASE U; CELL ADHESION; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; MONOCYTES; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, IGG; SERINE ENDOPEPTIDASES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84863704083     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-01-0011     Document Type: Article

References (46)

1. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7: 4-13.
2. Kilpatrick LM, Harris RL, Owen KA, et al. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood 2006; 108: 2616-2623.
3. Tkachuk VA, Plekhanova OS, Parfyonova YV. Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator. Can J Physiol Pharmacol 2009; 87: 231-251.
4. Schafer K, Konstantinides S, Riedel C, et al. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissuetype plasminogen activator. Circulation 2002; 106: 1847-1852.
5. Marcucci R, Brogi D, Sofi F, et al. PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting. Heart 2006; 92: 377-381.
6. Sinkovic A, Pogacar V. Risk stratification in patients with unstable angina and/or non-ST-elevation myocardial infarction by Troponin T and plasminogen-activator- inhibitor-1 (PAI-1). Thromb Res 2004; 114: 251-257.
7. Sargento L, Saldanha C, Monteiro J, et al. Evidence of prolonged disturbances in the haemostatic, hemorheologic and inflammatory profiles in transmural myocardial infarction survivors. Thromb Haemost 2003; 89: 892-903.
8. Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-2247.
9. Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057-2063.
10. Plouet J, Moro F, Bertagnolli S, et al. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 1997; 272: 13390-13396.
11. Traktuev DO, Tsokolaeva ZI, Shevelev AA, et al. Urokinase gene transfer augments angiogenesis in ischemic skeletal and myocardial muscle. Mol Ther 2007; 15: 1939-1946.
12. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99: 3050-3055.
13. Hoffmeister HM, Jur M, Wendel HP, et al. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 1995; 91: 2520-2527.
14. Halvorsen S, Huber K. The role of fibrinolysis in the era of primary percutaneous coronary intervention. Thromb Haemost 2011; 105: 390-395.
15. Maekawa Y, Anzai T, Yoshikawa T, et al. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol 2002; 39: 241-246.
16. Shantsila E, Lip GY. Monocytes in acute coronary syndromes. Arterioscler Thromb Vasc Biol 2009; 29: 1433-1438.
17. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74-80.
18. Shantsila E, Wrigley B, Tapp L, et al. Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. J Thromb Haemost 2011; 9: 1056-1066.
19. Shantsila E, Lip GY. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. Thromb Haemost 2009; 102: 916-924.
20. Hristov M, Leyendecker T, Schuhmann C, et al. Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb Haemost 2010; 104: 412-414.
21. Hristov M, Weber C. Differential role of monocyte subsets in atherosclerosis. Thromb Haemost 2011; 106: 757-762.
22. Soo KS, Northeast AD, Happerfield LC, et al. Tissue plasminogen activator production by monocytes in venous thrombolysis. J Pathol 1996; 178: 190-194.
23. Dejouvencel T, Doeuvre L, Lacroix R, et al. Fibrinolytic cross-talk: a new mechanism for plasmin formation. Blood 2010; 115: 2048-2056.
24. Castellote JC, Grau E, Linde MA, et al. Detection of both type 1 and type 2 plasminogen activator inhibitors in human monocytes. Thromb Haemost 1990; 63: 67-71.
25. Semeraro F, Ammollo CT, Semeraro N, et al. Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins. Haematologica 2009; 94: 819-826.
26. Lin JH, Garand M, Zagorac B, et al. Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells. Thromb Haemost 2011; 105: 999-1009.
27. Mishra N, Vercauteren E, Develter J, et al. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms. Thromb Haemost 2011; 106: 90-101.
28. Schulz C, von Bruhl ML, Barocke V, et al. EMMPRIN (CD147/basigin) mediates platelet-monocyte interactions in vivo and augments monocyte recruitment to the vascular wall. J Thromb Haemost 2011; 9: 1007-1019.
29. Bournazos S, Rennie J, Hart SP, et al. Monocyte functional responsiveness after PSGL-1-mediated platelet adhesion is dependent on platelet activation status. Arterioscler Thromb Vasc Biol 2008; 28: 1491-1498.
30. Passacquale G, Vamadevan P, Pereira L, et al. Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLoS One 2011; 6: e25595.
31. da Costa Martins PA, van Gils JM, Mol A, et al. Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins. J Leukoc Biol 2006; 79: 499-507.
32. di Santo A, Amore C, Dell'Elba G, et al. Glycogen synthase kinase-3 negatively regulates tissue factor expression in monocytes interacting with activated platelets. J Thromb Haemost 2011; 9: 1029-1039.
33. Yong AS, Pennings GJ, Chang M, et al. Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel. Blood 2011; 117: 11-20.
34. Furman MI, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1002-1006.
35. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
36. Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54: 281-292.
37. Kapiotis S, Jilma B, Quehenberger P, et al. Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. Circulation 1997; 96: 19-21.
38. Shantsila E, Tapp LD, Wrigley BJ, et al. The effects of exercise and diurnal variation on monocyte subsets and monocyte-platelet aggregates. Eur J Clin Invest 2012; epub ahead of print.
39. Pamukcu B, Lip GY, Shantsila E. The nuclear factor--kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease. Thromb Res 2011; 128: 117-123.
40. Minami E, Castellani C, Malchodi L, et al. The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair: urokinase attenuates ventricular remodeling. J Mol Cell Cardiol 2010; 49: 516-524.
41. Zhang Y, Zhou ZH, Bugge TH, et al. Urokinase-type plasminogen activator stimulation of monocyte matrix metalloproteinase-1 production is mediated by plasmin- dependent signaling through annexin A2 and inhibited by inactive plasmin. J Immunol 2007; 179: 3297-3304.
42. Pineda J, Marin F, Marco P, et al. The prognostic value of biomarkers after a premature myocardial infarction. Int J Cardiol 2010; 143: 249-254.
43. Paola Cellai A, Antonucci E, Alessandrello Liotta A, et al. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Thromb Res 2006; 118: 495-500.
44. Zorio E, Castello R, Falco C, et al. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 2003; 122: 958-965.
45. Seron MV, Plug T, Marquart JA, et al. Binding characteristics of thrombin-activatable fibrinolysis inhibitor to streptococcal surface collagen-like proteins A and B. Thromb Haemost 2011; 106: 609-616.
46. Tapp LD, Shantsila E, Wrigley BJ, et al. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. J Thromb Haemost 2011; epub ahead of print.